Group One Trading’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $295 | Sell |
225
-3,871
| -95% | -$5.35K | ﹤0.01% | 7352 |
|
|
2026
Q1 | $6.47K | Sell |
4,096
-2,407
| -37% | -$4.06K | ﹤0.01% | 6593 |
|
|
2025
Q4 | $10.9K | Buy |
+6,503
| New | +$11.3K | ﹤0.01% | 6770 |
|
|
2024
Q4 | – | Sell |
-745
| Closed | -$547 | – | 7645 |
|
|
2024
Q3 | $674 | Buy |
+745
| New | +$691 | ﹤0.01% | 6358 |
|
|
2023
Q3 | – | Sell |
-972
| Closed | -$1.32K | – | 7987 |
|
|
2023
Q2 | $1.37K | Hold |
972
| – | – | ﹤0.01% | 7190 |
|
|
2023
Q1 | $1.46K | Buy |
+972
| New | +$1.36K | ﹤0.01% | 6686 |
|
|
2021
Q4 | – | Sell |
-13,807
| Closed | -$32.3K | – | 8548 |
|
|
2021
Q3 | $35K | Buy |
+13,807
| New | +$35.4K | ﹤0.01% | 6813 |
|
|
2020
Q4 | – | Sell |
-10,279
| Closed | -$14.4K | – | 6762 |
|
|
2020
Q3 | $10K | Hold |
10,279
| – | – | ﹤0.01% | 5427 |
|
|
2020
Q2 | $9K | Hold |
10,279
| – | – | ﹤0.01% | 5166 |
|
|
2020
Q1 | $9K | Sell |
10,279
-6,900
| -40% | -$6.87K | ﹤0.01% | 4598 |
|
|
2019
Q4 | $15K | Buy |
+17,179
| New | +$14.3K | ﹤0.01% | 4462 |
|
|
2019
Q3 | – | Sell |
-22,865
| Closed | -$23.7K | – | 5356 |
|
|
2019
Q2 | $25K | Buy |
22,865
+3,010
| +15% | +$3.47K | ﹤0.01% | 4073 |
|
|
2019
Q1 | $26K | Buy |
19,855
+18,613
| +1,499% | +$23.2K | ﹤0.01% | 3911 |
|
|
2018
Q4 | $1K | Buy |
+1,242
| New | +$1.9K | ﹤0.01% | 4730 |
|
|
2018
Q1 | – | Sell |
-2,341
| Closed | -$5.49K | – | 5076 |
|
|
2017
Q4 | $4K | Sell |
2,341
-28,689
| -92% | -$62.6K | ﹤0.01% | 4611 |
|
|
2017
Q3 | $77K | Sell |
31,030
-3,811
| -11% | -$9.45K | ﹤0.01% | 3393 |
|
|
2017
Q2 | $96K | Buy |
34,841
+16,416
| +89% | +$45.9K | ﹤0.01% | 3132 |
|
|
2017
Q1 | $56K | Buy |
18,425
+6,490
| +54% | +$18.4K | ﹤0.01% | 3328 |
|
|
2016
Q4 | $38K | Buy |
+11,935
| New | +$36.6K | ﹤0.01% | 3410 |
|
|
2016
Q3 | – | Sell |
-7,766
| Closed | -$18K | – | 4724 |
|
|
2016
Q2 | $18K | Sell |
7,766
-20,468
| -72% | -$50.2K | ﹤0.01% | 3840 |
|
|
2016
Q1 | $71K | Sell |
28,234
-3,389
| -11% | -$7.56K | ﹤0.01% | 3054 |
|
|
2015
Q4 | $105K | Sell |
31,623
-44,213
| -58% | -$132K | ﹤0.01% | 2943 |
|
|
2015
Q3 | $184K | Sell |
75,836
-4,707
| -6% | -$12.2K | ﹤0.01% | 2562 |
|
|
2015
Q2 | $236K | Buy |
80,543
+44,858
| +126% | +$174K | ﹤0.01% | 2406 |
|
|
2015
Q1 | $143K | Sell |
35,685
-46,059
| -56% | -$159K | ﹤0.01% | 2640 |
|
|
2014
Q4 | $246K | Sell |
81,744
-4,485
| -5% | -$12.1K | ﹤0.01% | 2131 |
|
|
2014
Q3 | $219K | Buy |
86,229
+64,810
| +303% | +$156K | ﹤0.01% | 2302 |
|
|
2014
Q2 | $53K | Buy |
21,419
+11,358
| +113% | +$25.7K | ﹤0.01% | 3500 |
|
|
2014
Q1 | $27K | Sell |
10,061
-44,981
| -82% | -$132K | ﹤0.01% | 4054 |
|
|
2013
Q4 | $160K | Buy |
+55,042
| New | +$166K | ﹤0.01% | 2626 |
|
|
2013
Q3 | – | Sell |
-16,894
| Closed | -$53.5K | – | 5416 |
|
|
2013
Q2 | $54K | Buy |
+16,894
| New | +$54.1K | ﹤0.01% | 3368 |
|
Other funds holding LCTX
BC
DC
RA
Group One Trading's LCTX Position: Q2 2026 in Review
Group One Trading reduced its Lineage Cell Therapeutics (LCTX) stake by 95% in Q2 2026, selling an estimated $5.35K and leaving 225 shares worth $295. The position accounts for ﹤0.01% of the portfolio, ranked #7352.
Group One Trading first reported a position in LCTX in Q2 2013 and has held it in 31 quarters since. The position peaked at $246K in Q4 2014. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Group One Trading held 225 shares of Lineage Cell Therapeutics worth $295 as of Q2 2026.
- Group One Trading sold 3,871 Lineage Cell Therapeutics shares in Q2 2026, an estimated $5.35K.
- Lineage Cell Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7352 holding.
- Group One Trading first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 31 quarters since.
- Group One Trading's Lineage Cell Therapeutics position peaked at $246K in Q4 2014.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.